France

Sanofi - Aventis Group CEO魏巴赫announced April 21: The China and China Medical Association and the diabetes disease branch cooperation, a more than 46,000 cases, including diabetes and non-diabetic individuals of type II diabetes gene Research .

魏巴赫in Beijing at the forum said the study will take advantage of China has been The clinical data, in-depth analysis and type II diabetes-related genes, in order to help early detection of diabetes in high-risk groups, as well as to provide a new diabetes prevention and treatment options.

魏巴赫said Sanofi - Aventis will increase 90 million U.S. dollars (600 million yuan) investment in the expansion of Beijing Economic and Technological Development Zone glargine new insulin Pre-filled injection pen filling production lines, expansion of its production capacity will reach 50 million units of packaging to meet the growing Chinese market needs, enhance the national diabetes treatment standards.

In his view, as the world's fourth largest multi-national pharmaceutical enterprise groups, they focus on the Chinese market is extremely, and always focus on public health needs of China's investment in the field of diabetes treatment and management of the introduction of the highest level of research results China Gospel patients.

Sanofi - Aventis was the first to open an office in China the multinational pharmaceutical group, respectively, in Beijing, has a production base in Hangzhou. In 2007, investment 94 million U.S. dollars (700 million yuan) in Shenzhen to build high-tech influenza vaccine production base, launched in October last year, plans to expand the scale of China's research and development, accelerate drug target discovery, from the late-stage clinical trial studies of new drugs.